Life sciences · Observational Study
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05797649). This is a study registration, not published results. Lead sponsor: Chinese University of Hong Kong. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 160 participants (ACTUAL). Conditions: Pleural Effusion, Heart Failure, Malignant Neoplasm, Fluid Overload, Hypoalbuminemia, Renal Failure, Cirrhosis, Infections. Primary outcome measures: Comparison of the diagnostic performance of PF NTproBNP level in the diagnosis of HF-associated pleural effusions with other conventional biochemical criteria , 24 months. Brief summary: To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).